Document is current

Any future updates will be listed below

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

Crossref DOI link: https://doi.org/10.1186/s12886-017-0617-x

Published Online: 2017-12-04

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark